all report title image
  • Published On : May 2022
  • Code : CMI5031
  • Industry : Pharmaceutical
  • Pages : 150
  • Formats :

Sevoflurane is a type of anesthetic that belongs to the general anesthetics class of drugs. Before and during surgery, sevoflurane is used to induce general anesthesia (lack of consciousness). Sevoflurane is to be administered via inhalation. Although, sevoflurane can be used solely, it is frequently combined with other anesthetics. In some patients, this aids in the production of more effective anesthetic.

During surgery, sevoflurane also helps to keep the patient's blood pressure and pulse rate stable. Sevoflurane can also be used to help manage discomfort following surgery.

Global Sevoflurane Market - Impact of the Coronavirus (COVID-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 521 million cases and 6.27 million deaths due to coronavirus disease (COVID-19) were reported till May 20, 2022, across the globe.

Impact of COVID-19 on Demand and Supply of Sevoflurane

The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Many countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products.

However, there was no strong impact of COVID-19 on sevoflurane market as several inhalation anesthetic agents were used to sedate severely ill COVID-19 patients who required endotracheal intubation and mechanical ventilation. For instance, according to an article published in Lancet, April 2020, in both low- and high-income countries, the use of inhalational anesthetic medicines such as sevoflurane and isoflurane for ventilated COVID-19 patients is both practicable and cost-effective. These medications allow for precise and rapid management of sedation levels, and drug administration does not necessitate the use of electronic infusion pumps, which are in short supply.

The global sevoflurane market is estimated to be valued at US$ 370.2 Mn in 2022, and is expected to exhibit a CAGR of 4.4 % over the forecast period (2022-2030).

Figure 1: Global Sevoflurane Market Share (%) Analysis, By Application, 2022

Sevoflurane  | Coherent Market Insights

The increasing number of surgeries is the major factor that is expected to drive the growth of global sevoflurane market over the forecast period.

The emerging number of surgeries is expected to drive the growth of the global sevoflurane market. For instance, according to European Statistical System, 2021, per 100,000 inhabitants, 1094.3 cataract surgeries, 259.6 transluminal coronay angioplasty, 232.5 cholecystectomay, 219.5 inguinal hernia repair surgeries were performed in Belgium in 2018.

Prevalence of Chronic Disorders

Increasing number of chronic disorders like cancer, respiratory diseases, etc.  is expected to aid in the growth of the global sevoflurane market over the forecast period. For instance, according to GLOBOCAN 2020, an estimated 19.3 million new cancer cases (18.1 million excluding non-melanoma skin cancer) were diagnosed worldwide, with around 10.0 million cancer deaths (9.9 million excluding non-melanoma skin cancer) in 2020. With an anticipated 2.3 million new cases 11.7% were of female breast cancer followed by lung cancer (11.4 %), colorectal cancer (10.0%), prostate cancer (7.3 %), and stomach cancer (5.6 %) globally.

CMI table icon

Sevoflurane Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2022: US$ 370.2 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 4.4% 2030 Value Projection: US$ 522.8 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Application: Induction, Maintenance
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Abbott Laboratories, Baxter, Piramal Pharma Solutions, Manus Aktteva Biopharma LLP, Maruishi Pharmaceutical Co.,Ltd., Lunan Pharmaceutical Group, Abbvie, Wellona Pharma, Rewine Pharmaceutical, and Troikaa Pharmaceuticals Limited

Growth Drivers:
  • Increasing number of surgeries
  • Increasing prevalence of chronic disorders
  • Improving standards of surgical care
Restraints & Challenges:
  • Side effects of sevoflurane

Global Sevoflurane Market – Restraint

Side effects associated with sevoflurane are expected to hamper the growth of global sevoflurane market over forecast period. Side effects include-

  • Blurred vision
  • Pain, tightness, or discomfort in the chest
  • lightheadedness, dizziness
  • unusual tiredness or weakness
  • slow or irregular heartbeat

Global Sevoflurane Market – Regional Analysis

On the basis of region, the global sevoflurane market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold dominant position in the global sevoflurane market over the forecast period, owing to increasing standards of surgical care in the U.S. For instance, in July 2019, at the ACS Quality and Safety Conference, the American College of Surgeons (ACS) announced the introduction of its new Geriatric Surgery Verification (GSV) Program. This new surgical quality improvement initiative incorporates 30 new surgical criteria aimed at systematically improving surgical treatment and outcomes in the elderly.

Moreover, due to increasing number of surgeries, Asia Pacific is expected to witness a significant growth in the global sevoflurane market over the forecast period. For instance, according to the World Journal of Surgery, 2021, annually, 3646 procedures were performed to address the surgical needs of the Indian population, compared to 5000 surgeries per 100,000 people globally. Caesarean section, cataract surgery, fracture and hernia surgeries were the most common surgical procedures.        

Figure 2: Global Sevoflurane Market Value (US$ Mn), by Region, 2022

Sevoflurane  | Coherent Market Insights

Global Sevoflurane Market – Competitive Landscape

Major players operating in the global sevoflurane market include Abbott Laboratories, Baxter, Piramal Pharma Solutions, Manus Aktteva Biopharma LLP, Maruishi Pharmaceutical Co.,Ltd., Lunan Pharmaceutical Group, Abbvie, Wellona Pharma, Rewine Pharmaceutical, and Troikaa Pharmaceuticals Limited.

Sevoflurane is a sweet-smelling, nonflammable, highly fluorinated methyl isopropyl ether that is used as an inhalational anesthetic for general anesthesia induction and maintenance. It is the fastest-acting volatile anesthetic after desflurane.

Market Dynamics

Market players are focused on launching new technology to help delivery of anesthesia through inhalers, this could contribute to the growth of the global sevoflurane market over the forecast period. For instance, in April 2022, GE Healthcare, a leading global medical technology company, announced that its end-tidal (Et) Control software for general anesthesia delivery on its Aisys CS2 Anesthesia Delivery System has received pre-market approval (PMA) from the U.S. Food and Drug Administration (FDA). In the U.S., GE Healthcare is the only manufacturer approved to provide general anesthesia with end-tidal concentration control.

Increasing number of aesthetic surgeries requiring anesthesia, is expected to drive the growth of global sevoflurane market. For instance, in April 2022, The Aesthetic Society, world's leading association dedicated solely to facial and body aesthetic plastic surgery and cosmetic medicine issued its annual Aesthetic Plastic Surgery Statistics, which revealed that aesthetic plastic surgery increased in 2021 in U.S. owing to data acquired using the Society's new, more accurate digital technology. The data shows a large growth in procedures for the face, breasts, and body. Abdominoplasty, buttock augmentation, and liposuction have all seen a 63% surge in popularity since 2020 in U.S. Breast augmentation, augmentation/breast lift, and breast lift/reduction treatments all increased by 48%.

Increasing launches of technology to recycle inhaled anesthetics is expected to fuel the growth over forecast period. For instance, in July 2020, Baxter International Inc., a global leader in the production and delivery of sterile medications, announced a formal agreement with ZeoSys Medical, a medical technology company, to commercialize technology to capture and recycle anesthetic gases. Baxter will have worldwide distribution rights and an exclusive license to commercialize the technology outside of Europe, as well as an exclusive option to acquire ZeoSys Medical, under the terms of the agreement.

Key features of the study:

  • This report provides an in-depth analysis of global sevoflurane market, provides market size (US$ Million), and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global sevoflurane market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Abbott Laboratories, Baxter, Piramal Pharma Solutions, Manus Aktteva Biopharma LLP, Maruishi Pharmaceutical Co.,Ltd., Lunan Pharmaceutical Group, Abbvie, Wellona Pharma, Rewine Pharmaceutical, and Troikaa Pharmaceuticals Limited
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global sevoflurane market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global sevoflurane market.

Detailed Segmentation:

  • Global Sevoflurane Market, By Application:
    • Induction
    • Maintenance
  • Global Sevoflurane Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Sevoflurane Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Abbott Laboratories*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Baxter
    • Piramal Pharma Solutions
    • Manus Aktteva Biopharma LLP
    • Maruishi Pharmaceutical Co.,Ltd.
    • Lunan Pharmaceutical Group
    • Abbvie
    • Wellona Pharma
    • Rewine Pharmaceutical
    • Troikaa Pharmaceuticals Limited

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global sevoflurane market is expected to exhibit a CAGR of 4.4% during the forecast period (2022-2030).
The market is estimated to be valued at US$ 370.2 Mn in 2022.
Abbott Laboratories, Baxter, Piramal Pharma Solutions, Manus Aktteva Biopharma LLP, Maruishi Pharmaceutical Co.,Ltd., Lunan Pharmaceutical Group, Abbvie, Wellona Pharma, Rewine Pharmaceutical, and Troikaa Pharmaceuticals Limited are some of the prominent players operating in the market. .
The market is expected to be valued at US$ 522.8 Mn in 2030.
North America is the prominent region in the market.
Increasing number of surgeries, increasing prevalence of chronic disorders, and rise in improvement of surgical care by the market players are some of the driving factors, which are expected to drive growth of the market.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo